S G O'Brien

1.4k total citations · 1 hit paper
13 papers, 976 citations indexed

About

S G O'Brien is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, S G O'Brien has authored 13 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 12 papers in Genetics and 8 papers in Rheumatology. Recurrent topics in S G O'Brien's work include Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (8 papers). S G O'Brien is often cited by papers focused on Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (8 papers). S G O'Brien collaborates with scholars based in United Kingdom, United States and Germany. S G O'Brien's co-authors include Richard A. Larson, Brian Druker, Insa Gathmann, François Guilhot, John M. Goldman, Andreas Hochhaus, Manisha Mone, Timothy P. Hughes, Jerald P. Radich and Marc S. Rudoltz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gut.

In The Last Decade

S G O'Brien

13 papers receiving 945 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

2009 627 citations Andreas Hochhaus, S G O'Brien et al. Leukemia profile →

Peers

Countries citing papers authored by S G O'Brien

Since Specialization

Citations

This map shows the geographic impact of S G O'Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S G O'Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S G O'Brien more than expected).

Fields of papers citing papers by S G O'Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S G O'Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S G O'Brien. The network helps show where S G O'Brien may publish in the future.

Co-authorship network of co-authors of S G O'Brien

This figure shows the co-authorship network connecting the top 25 collaborators of S G O'Brien. A scholar is included among the top collaborators of S G O'Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S G O'Brien. S G O'Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia 2010 ·Haematologica ·Anne M. Dickinson, Kim Pearce, Jean Norden, S G O'Brien, Ernst Holler, Heike Bickeböller, Yesilda Balavarca, Vanderson Rocha, Hans‐Jochem Kolb, Ilona Hromadníková, Petr Sedláček, D Niederwieser, (unknown), Tapani Ruutu, Jane F. Apperley, Richard Szydlo, Els Goulmy, W. Siegert, T. de Witte, Aloïs Gratwohl	21
2	Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia breakdown → 2009 ·Leukemia ·Andreas Hochhaus, S G O'Brien, François Guilhot, Brian Druker, Susan Branford, Letizia Foroni, John M. Goldman, Martin Müller, Jerald P. Radich, Marc S. Rudoltz, Manisha Mone, Insa Gathmann, Timothy P. Hughes, Richard A. Larson, (unknown)	627
3	High rates of durable response are achieved with imatinib after treatment with interferon plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial 2009 ·Haematologica ·François Guilhot, Brian Druker, Richard A. Larson, Insa Gathmann, (unknown), Roger J. Waltzman, S G O'Brien	41
4	A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) 2007 ·Journal of Clinical Oncology ·Philipp le Coutre, Norbert Gattermann, Andreas Hochhaus, Richard A. Larson, (unknown), Md Ariful Haque, F. Giles, S G O'Brien, Hagop M. Kantarjian	3
5	A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP) 2006 ·Journal of Clinical Oncology ·Philipp D. le Coutre, Oliver G. Ottmann, (unknown), Richard A. Larson, Teresa Rafferty, Leila Alland, Ranjana Tavorath, F. Giles, S G O'Brien, Hagop M. Kantarjian	12
6	A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP). 2006 ·Blood ·Hagop M. Kantarjian, Norbert Gattermann, Andreas Hochhaus, Richard A. Larson, Teresa Rafferty, Aaron Weitzman, Md Ariful Haque, Francis J. Giles, S G O'Brien, Philipp le Coutre	18
7	A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) 2006 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, Norbert Gattermann, S G O'Brien, Kapil N. Bhalla, Andreas Hochhaus, (unknown), Leila Alland, (unknown), F. Giles, Philipp le Coutre	7
8	A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib 2005 ·Leukemia ·Lucy C. Crossman, Thomas O’Hare, Thoralf Lange, Stephanie G. Willis, Eric P. Stoffregen, A. Corbin, S G O'Brien, Michael C. Heinrich, Brian Druker, Peter G. Middleton, Michael W. Deininger	15
9	Gene Expression Profiling of CML CD34+ Cells Prior to Imatinib Therapy Reveals Differences between Patients with and without Subsequent Complete Cytogenetic Response. 2005 ·Blood ·Lucy C. Crossman, Marc Loriaux, Kristina Vartanian, Yaron Turpaz, Raju Pillai, S G O'Brien, Brian Druker, Shannon K. McWeeney, Christina A. Harrington, (unknown)	2
10	Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia 2003 ·British Journal of Cancer ·S G O'Brien, (unknown), (unknown), Joachim Beck, (unknown), Catherine Dutreix, (unknown), Slavica Milosavljev, Christoph Huber, Renaud Capdeville, Thomas Fischer	125
11	Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa 2003 ·Leukemia ·David Marín, Sarah Marktel, M Bua, Richard Szydlo, (unknown), Ilana Nathan, Natalie J. Foot, Charles Crawley, Thanyaphong Na Nakorn, Eduardo Olavarría, Anne Lennard, Annette Neylon, S G O'Brien, John M. Goldman, Jane F. Apperley	57
12	Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia. 1995 ·Journal of Clinical Oncology ·S G O'Brien, J M Goldman	13
13	Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion. 1995 ·Gut ·Adrian O’Callaghan, S G O'Brien, Mary Ninkovic, Graham P. Butcher, C.S. Foster, Julian R.F. Walters, Irene Roberts	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact